Concepts (274)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nanoparticles | 18 | 2022 | 318 | 4.290 |
Why?
|
| Drug Carriers | 10 | 2016 | 125 | 2.620 |
Why?
|
| Drug Delivery Systems | 12 | 2020 | 202 | 2.170 |
Why?
|
| Pharmaceutical Preparations | 4 | 2021 | 75 | 1.360 |
Why?
|
| Emulsions | 7 | 2021 | 33 | 1.280 |
Why?
|
| Nanotechnology | 6 | 2013 | 153 | 1.220 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2018 | 92 | 1.110 |
Why?
|
| Ionic Liquids | 2 | 2023 | 16 | 1.020 |
Why?
|
| Anthelmintics | 2 | 2021 | 18 | 0.970 |
Why?
|
| Benzoxazines | 3 | 2015 | 46 | 0.960 |
Why?
|
| Herpesvirus 1, Human | 2 | 2023 | 54 | 0.960 |
Why?
|
| Enema | 4 | 2018 | 10 | 0.950 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2018 | 149 | 0.900 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2020 | 63 | 0.860 |
Why?
|
| Gels | 5 | 2020 | 42 | 0.850 |
Why?
|
| Herpesvirus 2, Human | 2 | 2023 | 9 | 0.820 |
Why?
|
| Lecithins | 2 | 2011 | 2 | 0.800 |
Why?
|
| Animals | 34 | 2023 | 15081 | 0.780 |
Why?
|
| Cryptococcus neoformans | 1 | 2021 | 56 | 0.760 |
Why?
|
| Anti-HIV Agents | 7 | 2018 | 420 | 0.750 |
Why?
|
| Nanostructures | 2 | 2013 | 134 | 0.740 |
Why?
|
| HIV-1 | 5 | 2018 | 706 | 0.740 |
Why?
|
| Antifungal Agents | 3 | 2022 | 148 | 0.710 |
Why?
|
| Trigonella | 1 | 2019 | 2 | 0.700 |
Why?
|
| Malassezia | 1 | 2019 | 5 | 0.700 |
Why?
|
| Budesonide | 1 | 2018 | 5 | 0.660 |
Why?
|
| HIV Infections | 8 | 2022 | 2303 | 0.640 |
Why?
|
| Chromatography, High Pressure Liquid | 4 | 2015 | 421 | 0.620 |
Why?
|
| Nanocapsules | 2 | 2015 | 17 | 0.610 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 2017 | 4 | 0.590 |
Why?
|
| Drug Stability | 5 | 2019 | 116 | 0.580 |
Why?
|
| Organophosphorus Compounds | 1 | 2017 | 37 | 0.570 |
Why?
|
| Drug Design | 2 | 2016 | 162 | 0.570 |
Why?
|
| Antiviral Agents | 5 | 2023 | 157 | 0.550 |
Why?
|
| Colitis | 1 | 2017 | 65 | 0.550 |
Why?
|
| Sexually Transmitted Diseases, Viral | 1 | 2015 | 11 | 0.540 |
Why?
|
| Surface-Active Agents | 3 | 2011 | 41 | 0.530 |
Why?
|
| Drug Compounding | 7 | 2020 | 76 | 0.520 |
Why?
|
| Nanomedicine | 2 | 2013 | 35 | 0.510 |
Why?
|
| Cellulose | 1 | 2015 | 14 | 0.510 |
Why?
|
| Solubility | 6 | 2021 | 118 | 0.500 |
Why?
|
| Delayed-Action Preparations | 1 | 2015 | 60 | 0.500 |
Why?
|
| Tablets | 1 | 2014 | 9 | 0.500 |
Why?
|
| Cells | 1 | 2014 | 9 | 0.500 |
Why?
|
| Administration, Oral | 7 | 2021 | 224 | 0.480 |
Why?
|
| Hela Cells | 7 | 2023 | 366 | 0.480 |
Why?
|
| Lipids | 4 | 2023 | 235 | 0.480 |
Why?
|
| Herpes Genitalis | 2 | 2023 | 6 | 0.460 |
Why?
|
| Skin | 3 | 2021 | 174 | 0.460 |
Why?
|
| Pyrrolidinones | 1 | 2012 | 7 | 0.430 |
Why?
|
| Particle Size | 6 | 2019 | 215 | 0.430 |
Why?
|
| beta-Cyclodextrins | 2 | 2011 | 24 | 0.430 |
Why?
|
| Fats | 1 | 2011 | 2 | 0.400 |
Why?
|
| Oils | 1 | 2011 | 6 | 0.400 |
Why?
|
| Colon | 3 | 2018 | 103 | 0.390 |
Why?
|
| Quercetin | 1 | 2011 | 45 | 0.370 |
Why?
|
| Phospholipids | 1 | 2011 | 70 | 0.370 |
Why?
|
| Liposomes | 2 | 2008 | 118 | 0.350 |
Why?
|
| Humans | 26 | 2023 | 37093 | 0.350 |
Why?
|
| Drug Evaluation, Preclinical | 4 | 2016 | 112 | 0.340 |
Why?
|
| Ketorolac | 1 | 2008 | 1 | 0.330 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2011 | 121 | 0.330 |
Why?
|
| Poloxamer | 3 | 2022 | 9 | 0.330 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2022 | 201 | 0.320 |
Why?
|
| Propofol | 1 | 2008 | 8 | 0.310 |
Why?
|
| Rats | 6 | 2021 | 3483 | 0.310 |
Why?
|
| Trinitrobenzenesulfonic Acid | 2 | 2018 | 20 | 0.310 |
Why?
|
| Heptanoic Acids | 1 | 2007 | 12 | 0.310 |
Why?
|
| Hypercholesterolemia | 1 | 2007 | 38 | 0.300 |
Why?
|
| Antiparasitic Agents | 1 | 2007 | 8 | 0.300 |
Why?
|
| Parasitic Diseases | 1 | 2007 | 6 | 0.300 |
Why?
|
| Pyrroles | 1 | 2007 | 55 | 0.300 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2007 | 77 | 0.290 |
Why?
|
| Ceftizoxime | 1 | 2006 | 1 | 0.290 |
Why?
|
| Cisplatin | 2 | 2017 | 72 | 0.290 |
Why?
|
| Polymers | 3 | 2020 | 121 | 0.280 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2022 | 94 | 0.280 |
Why?
|
| Rabbits | 4 | 2021 | 283 | 0.280 |
Why?
|
| Mice | 11 | 2023 | 5913 | 0.270 |
Why?
|
| Cyclopropanes | 3 | 2015 | 40 | 0.260 |
Why?
|
| Alkynes | 3 | 2015 | 50 | 0.260 |
Why?
|
| Pain | 1 | 2008 | 251 | 0.250 |
Why?
|
| Temperature | 3 | 2016 | 286 | 0.250 |
Why?
|
| Antineoplastic Agents | 4 | 2017 | 803 | 0.240 |
Why?
|
| Administration, Intravesical | 2 | 2020 | 5 | 0.230 |
Why?
|
| Herpesviridae Infections | 1 | 2023 | 18 | 0.230 |
Why?
|
| Thiophenes | 1 | 2023 | 31 | 0.230 |
Why?
|
| Diffusion | 3 | 2015 | 50 | 0.220 |
Why?
|
| Anti-Bacterial Agents | 1 | 2006 | 352 | 0.220 |
Why?
|
| Water Purification | 1 | 2023 | 28 | 0.220 |
Why?
|
| Suspensions | 2 | 2018 | 46 | 0.220 |
Why?
|
| Tinea | 1 | 2022 | 7 | 0.220 |
Why?
|
| Vaginal Creams, Foams, and Jellies | 3 | 2018 | 5 | 0.220 |
Why?
|
| Pyrimidines | 1 | 2023 | 118 | 0.210 |
Why?
|
| Malvaceae | 1 | 2022 | 4 | 0.210 |
Why?
|
| Lignans | 1 | 2022 | 21 | 0.210 |
Why?
|
| Dioctyl Sulfosuccinic Acid | 1 | 2021 | 1 | 0.200 |
Why?
|
| Candidiasis | 1 | 2022 | 84 | 0.200 |
Why?
|
| Biological Transport | 2 | 2016 | 185 | 0.200 |
Why?
|
| Coumarins | 1 | 2022 | 38 | 0.200 |
Why?
|
| Male | 10 | 2022 | 20025 | 0.200 |
Why?
|
| Central Nervous System Diseases | 1 | 2022 | 29 | 0.200 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2020 | 1618 | 0.200 |
Why?
|
| Rectum | 2 | 2018 | 22 | 0.200 |
Why?
|
| Benzimidazoles | 1 | 2021 | 36 | 0.200 |
Why?
|
| Parkinson Disease, Secondary | 1 | 2021 | 10 | 0.200 |
Why?
|
| Indans | 1 | 2021 | 13 | 0.200 |
Why?
|
| Reperfusion Injury | 1 | 2022 | 57 | 0.200 |
Why?
|
| Administration, Topical | 4 | 2020 | 40 | 0.200 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 2021 | 25 | 0.190 |
Why?
|
| Adenine | 2 | 2018 | 44 | 0.190 |
Why?
|
| Ointments | 1 | 2020 | 1 | 0.190 |
Why?
|
| Acyclovir | 1 | 2020 | 5 | 0.190 |
Why?
|
| Carboxylic Acids | 1 | 2020 | 13 | 0.190 |
Why?
|
| Ophthalmic Solutions | 1 | 2020 | 18 | 0.190 |
Why?
|
| Disease Models, Animal | 6 | 2022 | 1371 | 0.190 |
Why?
|
| Eye | 1 | 2020 | 71 | 0.180 |
Why?
|
| Strongylida Infections | 1 | 2020 | 25 | 0.180 |
Why?
|
| Butylated Hydroxytoluene | 1 | 2019 | 2 | 0.180 |
Why?
|
| Xanthophylls | 1 | 2019 | 15 | 0.170 |
Why?
|
| Angiostrongylus cantonensis | 1 | 2020 | 32 | 0.170 |
Why?
|
| Skin Absorption | 3 | 2008 | 15 | 0.170 |
Why?
|
| Immunotherapy | 1 | 2020 | 95 | 0.170 |
Why?
|
| Reactive Oxygen Species | 1 | 2022 | 461 | 0.170 |
Why?
|
| NF-kappa B | 1 | 2022 | 339 | 0.170 |
Why?
|
| Polyglycolic Acid | 3 | 2016 | 37 | 0.170 |
Why?
|
| Surface Properties | 1 | 2019 | 130 | 0.170 |
Why?
|
| Progestins | 1 | 2018 | 12 | 0.170 |
Why?
|
| Plant Leaves | 1 | 2019 | 124 | 0.170 |
Why?
|
| Neuroprotective Agents | 1 | 2022 | 245 | 0.170 |
Why?
|
| Mucus | 1 | 2018 | 15 | 0.160 |
Why?
|
| Polystyrenes | 1 | 2018 | 19 | 0.160 |
Why?
|
| Lactic Acid | 3 | 2016 | 95 | 0.160 |
Why?
|
| Progesterone | 1 | 2018 | 113 | 0.160 |
Why?
|
| HIV | 2 | 2022 | 98 | 0.160 |
Why?
|
| Infusions, Parenteral | 2 | 2008 | 12 | 0.160 |
Why?
|
| Prodrugs | 1 | 2018 | 24 | 0.160 |
Why?
|
| Anti-Infective Agents | 1 | 2018 | 64 | 0.150 |
Why?
|
| Premature Birth | 1 | 2018 | 75 | 0.150 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2017 | 57 | 0.150 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 1609 | 0.150 |
Why?
|
| Glioma | 1 | 2017 | 79 | 0.140 |
Why?
|
| Feasibility Studies | 2 | 2021 | 208 | 0.140 |
Why?
|
| Antioxidants | 1 | 2019 | 416 | 0.140 |
Why?
|
| Intestinal Mucosa | 1 | 2017 | 122 | 0.130 |
Why?
|
| Primary Prevention | 1 | 2016 | 59 | 0.130 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 111 | 0.130 |
Why?
|
| Gastrointestinal Tract | 1 | 2016 | 61 | 0.130 |
Why?
|
| Biological Availability | 2 | 2021 | 88 | 0.130 |
Why?
|
| Mice, Inbred BALB C | 1 | 2017 | 661 | 0.130 |
Why?
|
| Calorimetry, Differential Scanning | 2 | 2011 | 30 | 0.120 |
Why?
|
| RNA, Viral | 1 | 2016 | 301 | 0.120 |
Why?
|
| Administration, Cutaneous | 2 | 2021 | 43 | 0.120 |
Why?
|
| Chemistry, Pharmaceutical | 3 | 2011 | 71 | 0.120 |
Why?
|
| Microscopy, Electron, Transmission | 2 | 2011 | 146 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 481 | 0.120 |
Why?
|
| Tissue Distribution | 2 | 2018 | 207 | 0.110 |
Why?
|
| AIDS Vaccines | 1 | 2013 | 30 | 0.110 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 562 | 0.110 |
Why?
|
| Phagocytosis | 1 | 2012 | 69 | 0.110 |
Why?
|
| Soybean Proteins | 1 | 2012 | 38 | 0.100 |
Why?
|
| Membranes, Artificial | 2 | 2023 | 28 | 0.100 |
Why?
|
| Polysaccharides | 1 | 2012 | 58 | 0.100 |
Why?
|
| Carbamazepine | 1 | 2011 | 5 | 0.100 |
Why?
|
| Time Factors | 2 | 2016 | 1742 | 0.100 |
Why?
|
| Polymethacrylic Acids | 1 | 2011 | 1 | 0.100 |
Why?
|
| Thiazines | 1 | 2011 | 3 | 0.100 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2011 | 34 | 0.100 |
Why?
|
| Diglycerides | 1 | 2011 | 10 | 0.100 |
Why?
|
| Anticonvulsants | 1 | 2011 | 34 | 0.100 |
Why?
|
| Carbamates | 1 | 2011 | 12 | 0.100 |
Why?
|
| Epilepsy | 1 | 2011 | 43 | 0.100 |
Why?
|
| Glucose Tolerance Test | 1 | 2011 | 68 | 0.100 |
Why?
|
| Cell Line | 2 | 2013 | 1354 | 0.100 |
Why?
|
| Cryoelectron Microscopy | 1 | 2011 | 43 | 0.100 |
Why?
|
| Thiazoles | 1 | 2011 | 74 | 0.100 |
Why?
|
| Polysorbates | 1 | 2010 | 10 | 0.100 |
Why?
|
| Deoxycholic Acid | 1 | 2010 | 10 | 0.100 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 409 | 0.100 |
Why?
|
| Piperidines | 1 | 2011 | 77 | 0.090 |
Why?
|
| Micelles | 1 | 2010 | 32 | 0.090 |
Why?
|
| Transfection | 1 | 2011 | 523 | 0.090 |
Why?
|
| Doxorubicin | 1 | 2010 | 84 | 0.090 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2011 | 208 | 0.090 |
Why?
|
| Tretinoin | 2 | 2007 | 50 | 0.090 |
Why?
|
| Cell Proliferation | 1 | 2015 | 1198 | 0.080 |
Why?
|
| Blood Glucose | 1 | 2011 | 353 | 0.080 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2007 | 364 | 0.080 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2008 | 98 | 0.080 |
Why?
|
| Cricetinae | 1 | 2008 | 238 | 0.080 |
Why?
|
| Chemistry, Physical | 1 | 2008 | 45 | 0.080 |
Why?
|
| Chemical Phenomena | 1 | 2008 | 54 | 0.080 |
Why?
|
| Female | 6 | 2020 | 20969 | 0.080 |
Why?
|
| Administration, Intravaginal | 2 | 2018 | 8 | 0.080 |
Why?
|
| Materials Testing | 1 | 2008 | 69 | 0.080 |
Why?
|
| Keratolytic Agents | 1 | 2007 | 3 | 0.080 |
Why?
|
| Colloids | 1 | 2007 | 17 | 0.070 |
Why?
|
| Polyethylene Glycols | 2 | 2017 | 84 | 0.070 |
Why?
|
| Skin Aging | 1 | 2006 | 10 | 0.070 |
Why?
|
| Retinoids | 1 | 2006 | 28 | 0.070 |
Why?
|
| Homosexuality, Male | 2 | 2022 | 458 | 0.060 |
Why?
|
| Liver | 1 | 2007 | 479 | 0.060 |
Why?
|
| Cell Line, Tumor | 3 | 2017 | 2231 | 0.060 |
Why?
|
| Peptides | 2 | 2017 | 320 | 0.060 |
Why?
|
| Genitalia | 1 | 2023 | 17 | 0.060 |
Why?
|
| Distillation | 1 | 2023 | 2 | 0.060 |
Why?
|
| Crystallization | 1 | 2023 | 86 | 0.060 |
Why?
|
| Minerals | 1 | 2023 | 47 | 0.060 |
Why?
|
| Macaca | 1 | 2022 | 38 | 0.050 |
Why?
|
| Biguanides | 1 | 2022 | 7 | 0.050 |
Why?
|
| Niclosamide | 1 | 2022 | 8 | 0.050 |
Why?
|
| Fluconazole | 1 | 2022 | 41 | 0.050 |
Why?
|
| Candida | 1 | 2022 | 40 | 0.050 |
Why?
|
| Cell Survival | 2 | 2017 | 864 | 0.050 |
Why?
|
| Skin Tests | 1 | 2021 | 14 | 0.050 |
Why?
|
| Rotenone | 1 | 2021 | 19 | 0.050 |
Why?
|
| Hydrogels | 1 | 2021 | 37 | 0.050 |
Why?
|
| Hypotonic Solutions | 1 | 2020 | 2 | 0.050 |
Why?
|
| Candida albicans | 1 | 2022 | 164 | 0.050 |
Why?
|
| Biofilms | 1 | 2022 | 168 | 0.050 |
Why?
|
| Locomotion | 1 | 2021 | 97 | 0.050 |
Why?
|
| Larva | 1 | 2020 | 124 | 0.040 |
Why?
|
| Plant Roots | 1 | 2022 | 158 | 0.040 |
Why?
|
| Swine | 1 | 2020 | 184 | 0.040 |
Why?
|
| Microscopy, Electron, Scanning | 2 | 2011 | 142 | 0.040 |
Why?
|
| Administration, Rectal | 1 | 2018 | 18 | 0.040 |
Why?
|
| Technology, Pharmaceutical | 2 | 2011 | 27 | 0.040 |
Why?
|
| Alanine | 1 | 2018 | 30 | 0.040 |
Why?
|
| Osmolar Concentration | 1 | 2017 | 58 | 0.040 |
Why?
|
| Biotransformation | 1 | 2017 | 67 | 0.040 |
Why?
|
| Animals, Newborn | 1 | 2018 | 343 | 0.040 |
Why?
|
| Macaca mulatta | 1 | 2017 | 128 | 0.040 |
Why?
|
| Cadaverine | 1 | 2017 | 4 | 0.040 |
Why?
|
| Carbocyanines | 1 | 2017 | 14 | 0.040 |
Why?
|
| Microbubbles | 1 | 2017 | 20 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2017 | 92 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2017 | 77 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2017 | 185 | 0.040 |
Why?
|
| Emulsifying Agents | 1 | 2016 | 2 | 0.040 |
Why?
|
| Fluorescent Dyes | 1 | 2017 | 181 | 0.030 |
Why?
|
| Vagina | 1 | 2016 | 81 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 357 | 0.030 |
Why?
|
| Viral Load | 1 | 2016 | 312 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 617 | 0.030 |
Why?
|
| Pregnancy | 1 | 2018 | 1549 | 0.030 |
Why?
|
| U937 Cells | 1 | 2013 | 27 | 0.030 |
Why?
|
| Subcellular Fractions | 1 | 2013 | 77 | 0.030 |
Why?
|
| Capsules | 1 | 2012 | 25 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 227 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2013 | 218 | 0.030 |
Why?
|
| Pentylenetetrazole | 1 | 2011 | 6 | 0.030 |
Why?
|
| Spectrophotometry, Infrared | 1 | 2011 | 37 | 0.030 |
Why?
|
| Stomach Ulcer | 1 | 2011 | 5 | 0.030 |
Why?
|
| X-Ray Diffraction | 1 | 2011 | 57 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2013 | 259 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2011 | 289 | 0.020 |
Why?
|
| Brain | 1 | 2017 | 1346 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2011 | 808 | 0.020 |
Why?
|
| Irritants | 1 | 2007 | 8 | 0.020 |
Why?
|
| Erythema | 1 | 2007 | 10 | 0.020 |
Why?
|
| Rheology | 1 | 2007 | 25 | 0.020 |
Why?
|
| Solvents | 1 | 2007 | 99 | 0.020 |
Why?
|
| Dermis | 1 | 2006 | 8 | 0.020 |
Why?
|
| Dermatologic Agents | 1 | 2006 | 9 | 0.020 |
Why?
|
| Vitamin A Deficiency | 1 | 2006 | 13 | 0.020 |
Why?
|
| Retinaldehyde | 1 | 2006 | 21 | 0.020 |
Why?
|
| Nicotinic Acids | 1 | 2006 | 8 | 0.020 |
Why?
|
| Epidermis | 1 | 2006 | 24 | 0.020 |
Why?
|
| Naphthalenes | 1 | 2006 | 38 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2004 | 14 | 0.020 |
Why?
|
| Naproxen | 1 | 2004 | 7 | 0.020 |
Why?
|
| Young Adult | 1 | 2012 | 4268 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2006 | 1369 | 0.010 |
Why?
|
| Adult | 1 | 2012 | 11712 | 0.010 |
Why?
|